Quidel社では組織適合性試験、アルツハイマー病、全身性エリテマトーデス、加齢性黄斑変性、溶血性尿毒症症候群など多くの研究分野において有用な幅広い補体関連モノクローナル抗体(mAb)コレクションを提供しています。

これらの抗体は多くのアプリケーションにおいて徹底的に実証された高品質マウスモノクローナル抗体で、参考文献も豊富にございます。
Quidel社の抗補体モノクローナル抗体は全てHumanに対して反応します。Cross Reactivityについてはデータシートをご確認ください。

抗補体モノクローナル抗体

General Complement Activation

製品番号：A207
C3 / C3d mAb全身性エリトマトーデス(SLE)[A],関節リウマチ(RA)[B]および非炎症性標本[C]の大動脈組織におけるC3dの沈着

Shields KJ, Mollnes TE, Eidet JR, Mikkelsen K, Almdahl SM, et al. (2017) Plasma complement and vascular complement deposition in patients with coronary artery disease with and without inflammatory rheumatic diseases. PLOS ONE 12(3): e0174577.

Classical and Lectin Pathway

製品番号：A211, A213
・C4 / C4c mAb
・C4 / C4d mAb
非免疫ヒト血清中の細菌培養後のフローサイトメトリーによるS.pyogenes表面上のC4c, C4d沈着分析結果

Carlsson, F., Berggard, K., Stalhammar-Carlemalm, M., and Lindahl, G. Evasion of Phagocytosis through Cooperation between Two Ligand-binding Regions in Streptococcus pyogenes M Protein (2003)J. Exp.Med.198,1057-1068

Alternative Pathway

製品番号：A252
Factor B(Bb)(neo) mAb Factor BおよびFactor Dの共培養(奇数レーン), Factor B, Factor D 及びC3bの共培養(偶数レーン)
(A)Asp-715変異体 (B)F716A変異体

Hourcade, D., et al. A Conserved Element in the Serine Protease Domain of Complement Factor B, J Bio Chem 273:25996-26000, 1998.

Terminal Complement Complex

製品番号：A239
SC5b-9 mAb
SSc患者の皮膚内皮細胞におけるMAC（膜侵襲複合体）またはC5b-9の検出C5b-9特異抗体（オレンジ）による8人のSSc患者（4病変SSc皮膚および4非病変SSc皮膚）、 8人の健康な被験者および4人のScGVHD患者の皮膚サンプルの免疫染色結果

抗CD31抗体（緑色）を内皮細胞マーカーとして使用し、DAPIにより核染色をした。

TScambi C, Ugolini,S, Jokiranta TS, De Franceschi L, Bortolami O, et al. (2015) The Local Complement Activation on Vascular Bed of Patients with Systemic Sclerosis: A Hypothesis-Generating Study. PLOS ONE 10(2): e0114856.

Regulatory Proteins

製品番号：A235
Factor P (#2) mAb
Anti-Properdinを用いたフローサイトメトリーによるグリカン結合プロペルジンの検出

正常ヒト血清（NHS）およびプロペルジン欠乏（P-枯渇）血清をそれぞれプロペルジン結合の 陽性対照および陰性対照として用いた。

Agarwal S, et al. (2011) Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans. mBio 2(5): e00178-11.

上記以外の製品ラインアップも多数ございます。詳しくはQuidel社の製品カタログをご覧ください。

PDFカタログを見る

Quidel 社が運営する 補体関連情報サイト「It's Complementary」では、補体に関する最新の情報を無料で検索することができます。
タンパク質および疾患、研究分野のリストからご興味のあるキーワードを登録することで、関連情報を毎週メールで配信する機能もございます。

It's Complementaryのご利用方法についてはこちら

参考文献：General Complement Activation

• Tamerius, J.D., Pangburn, M., et al. Detection of a neoAntigen on human iC3b and C3d by monoclonal Antibody, J. Immunol. 135:2015, 1985.
• Tamerius, J.D., Pangburn, M., et al. Selective inhibition of functional sites of cell bound C3b by hybridoma derived antibodies, J. Immunol 128:512, 1982.
• Murray,I. et al. Functional bioactive recombinant acylation stimulating protein is distinct from C3a anaphylatoxin. J Lipid Res. Sci. 38(12):2492-2501 (1997)

• Tamerius, J.D., Pangburn, M., et al. Detection of a neoantigen on human iC3b and C3d by monoclonal Antibody, J. Immunol. 135:2015, 1985.
• Rogers, J., Cooper, N., et al. Complement Activation by Β-amyloid in Alzheimer disease, PNAS 89:10016-10020, 1992.
• Gemmell, C. A flow cytometric immunoassay to quantify adsorption of complement activation products on artificial surfaces, J Biomed Mater Res 37, 474-480, 1997.
• Merri, S., Junnikala, S. Exceptional Resistance of Human H2 Gioblastoma Cells to Complement Mediated Killing by Expression and Utilization of Factor H and Factor H Like Protein 1, J Immunol 164:11 6075-6081, 2000.
• Marks, R., Hindmarsh, E. Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells, J Immunol 160:6128-6136, 1998.
• Buyon, J.P.,Tamerius J., Belmont H.M., Abramson S.B., Assessment of disease activity and impending lupusflare in patients with SLE. Arthritis and Rheumatism 35:1028-37, 1992.
• Grehan J.F., Levay-Young B.K., Fogelson J.L., Francois-Bongarcon V, Benson B.A., Dalmasso A.P., "IL-4 and IL-13 Induce Protection of Porcine Endothelial Cells From Killing by Human Complement and From Apoptosis Through Activation of a Phosphatidylinositide 3-Kinase/Akt Pathway" J Immun 175:1903-10, 2005.
• Salerno C.T., Kulick D.M., Yeh C.G., Guzman-Paz M,Higgins P.J., Benson B.A., Park S.J., Shumway S.J., Bolman R.M., Dalmasso A.P., "A Soluble Chimeric Inhibitor of C3 an C5 Convertases, Complement Activation Blocker-2, Prolongs Graft Survival in Pig-To-Rhesus Monkey Heart Transplantation" Xenotransplantation 9:125-34, 2002.
• Ferguson J.S., Weis J.J., Martin J.L., Schlesinger L.S., "Complement Protein C3 binding to Mycobacteriumtuberculosis is Initiated by the Classical Pathway inHuman Brochoalveolar Lavage Fluid" Infect and Immun 72(5):2564-73 2004.
• Mevorach D, Mascarenhas J.O., Gershov D, Elkon K.B., "Complement-dependent Clearance of Apoptotic Cells by Human Macrophages" J Exp Med 188(12):2313-20, 1998.
• Gershov D, Kim S, Brot N, Elkon K.B., "C-Reactive Protein Binds to Apoptotic Cells, Protects the Cells from Assembly of the Terminal Complement Components, and Sustains an Antiinflammatory Innate Immune Response: Implications for Systemic Autoimmunity" J Exp Med 192(9):1353-63, 2000.

• Tamerius, J.D., Pangburn, M.K., et al. Detection of a neoantigen on human iC3b and C3d by monoclonal Antibody, J. Immunol. 135:2015, 1985.
• Tamerius, J.D., Pangburn, M.K., et al. Selective inhibition of functional sites of cell bound C3b by hybridoma derived antibodies, J. Immunol 128:512, 1982.
• Barilla -LaBarca, M.L. et al. "Role of Membrane Cofactor Protein (CD46) in regulation of C4b and C3b Deposited Cells"Jimmunol (2002) 168:6298-6304.
• `Pascher A, Poehlein C, Storck M, Prestel R, Mueller-Hoecker J, White D.J.G., Abendroth D, Hammer C.,"Immunopathological Observations After Xenogeneic Liver Perfusions Using Donor Pigs Transgenic for Human Decay-Accelerating Factor 1,2"Transplantation 64(3):384-91, 1997.
• Mieller-Ortiz S.L., Wanger A.R., Norris S.J., "Mycobacterial Protein HbhA Binds Human Complement Component C3"Infect and Immun 69(12):7501-11, 2001.
• Grehan J.F., Levay-Young B.K., Fogelson J.L., Francois-Bongarcon V, Benson B.A., Dalmasso A.P.,"IL-4 and IL-13 Induce Protection of Porcine Endothelial Cells From Killing by Human Complement and From Apoptosis Through Activation of a Phosphatidylinositide 3-Kinase/Akt Pathway"JImmun 175:1903-10,2005.

• Shields KJ, Mollnes TE, Eidet JR, Mikkelsen K, Almdahl SM, et al. (2017) Plasma complement and vascular complement deposition in patients with coronary artery disease with and without inflammatory rheumatic diseases. PLOS ONE 12(3): e0174577.
• Perez LG, Martinez DR, deCamp AC, Pinter A, Berman PW, et al. (2017) V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. PLOS ONE 12(7): e0180720.
• Seddon JM, Yu Y, Miller EC, et al. Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nature genetics. 2013;45(11):1366-1370.
• Martini PG, Cook LC, Alderucci S, et al. Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases. BMC Immunology. 2010;11:43.
• Carlsson F, Berggård K, Stålhammar-Carlemalm M, Lindahl G. Evasion of Phagocytosis through Cooperation between Two Ligand-binding Regions in Streptococcus pyogenes M Protein. The Journal of Experimental Medicine. 2003;198(7):1057-1068.
• Stoltzner, S., Lemere, C. et al. Temporal accrual of complement proteins in Amyloid plaques in patients with Down syndrome with Alzheimer's Disease, Am J Path 156:489-499, 2000.
• Gemmell, C. A flow cytometric immunoassay to quantify adsorption of complement activation products on artificial surfaces, J Biomed Mater Res 37, 474-480, 1997.
• Rogers, J., Cooper, N., et al. Complement Activation by Β-amyloid in Alzheimer disease. PNAS 89:10016-10020, 1992.
• Tamerius, J.D., Pangburn, M.K., et al. Selective inhibition of functional sites of cell bound C3b by hybridoma derived antibodies, J. Immunol 128:512, 1982.
• Tamerius, J.D., Pangburn, M.K., et al. Detection of a neoAntigen on human iC3b and C3d by monoclonal Antibody, J. Immunol. 135:2015, 1985.
• Barilla-LaBarca, M.L. et al. "Role of Membrane Cofactor Protein (CD46) in regulation of C4b and C3b Deposited Cells"Jimmunol (2002) 168:6298-6304.
• Pascher A, Poehlein C, Storck M, Prestel R, Mueller-Hoecker J, White D.J.G., Abendroth D, Hammer C.,"Immunopathological Observations After Xenogeneic Liver Perfusions Using Donor Pigs Transgenic for Human Decay-Accelerating Factor 1,2"Transplantation 64(3):384-91, 1997.
• Yasojima K, Schwab C, McGeer E.G., McGeer P.L.,"Up-Regulated Production and Activation of the Complement System in Alzheimer's Disease Brain"Am J Pathol 154(3):927-36, 1999.
• Yasojima K, Schwab C, McGeer E.G., McGeer P.L., "Generation of C-Reactive Protein and Complement Components in Atherosclerotic Plaques"Am J Pathol 158(3):1039-51, 2001.

• Tamerius, J.D., Pangburn, M.K., et al. Detection of a neoAntigen on human iC3b and C3d by monoclonal Antibody, J. Immunol. 135:2015, 1985.
• Tamerius, J.D., Pangburn, M.K., et al. Selective inhibition of functional sites of cell bound C3b by hybridoma derived antibodies, J. Immunol 128:512, 1982.
• Rogers, J., Cooper, N., et al. Complement Activation by Β-amyloid in Alzheimer disease. PNAS 89:10016-10020, 1992.
• Barilla-LaBarca, M.L. et al. "Role of Membrane Cofactor Protein (CD46) in regulation of C4b and C3b Deposited Cells"Jimmunol (2002) 168:6298-6304.
• Baldwin W.M., Samaniego-Picota M, Kasper E.K., Clark A.M., Czader M, Rohde C, Zachary A.A., Sanfilippo F, Hruban R.H., "Complement Deposition in Early Cardiac Transplant Biopsies is Associated With Ischemic Injury and Subsequent Rejection Episodes"Transplantation 68(6):894-900, 1999.

参考文献：Classical and Lectin Pathway

• Solzner, S., Lemerre, C. et al. Temporal accrual of complement proteins in Amyloid plaques in patients with Down syndrome with Alzheimer's Disease, Am J Path 156:489-499, 2000.
• Gershov D, Kim S.J., Brot N., Elkon K.B., "CReactive Protein Binds to Apoptotic Cells, Protects the Cells from Assembly of the Terminal Complement Components, and Sustains Antiinflammatory Innate Immune Response: Implications for Systemic Autoimmunity" J Exp Med 192(9), 2000.
• Rogers J, Cooper N.R., Webster S, Schultz J, McGeer P.L., Styren S.D., Civin W.H., Brachova L, Bradt B, Ward P, Lieberburg I, "Complement Activation By b-amyloid in Alzheimer Disease" Proc Natl Acad Sci 89:10016-20, 1992.
• Jack D.L.,Dodds A.W.,Anwar N, Ison C.A., Law A, Frosch M, Turner M.W., Klein N.J., "Activation of Complement by Mannose-Binding Lectin on Isogenic Mutants of Neisseria meningitides Serogroup B1" J Immunol 160:1346-53, 1998.
• Gemmell C.H."A Flow Cytometric Immunoassay to Quantify Adsorption of Complement Activation Products (iC3b, C3d, SC5b-9) on Artificial Surfaces"J Biomed Mater Res 37(4):474-80, 1997.

• Pascher, A. et al. Immunopathological observations after xenogeneic liver perfusions using donor pigs transgenic for human decayaccelerating factor 1,2. Transplantation 64:384-391 (1997).
• Barilla-LaBarca, M.L. et al. Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells. J Immunol 168:6298-6304 (2002).
• Barbosa, A., et al. Immune evasion of lptospira species by acquisition of human complement regulator C4BP. Infection and Immunity 77.3:1137-143 (2009)

• Rogers, J., Cooper, N., et al. Complement Activation by ss-amyloid in Alzheimer disease, PNAS 89:10016-10020, 1992.
• Schwab, C. Steele, J.C. McGeer, P.L. Neurofibrillary tangles of Guam parkinson-dementia are associated with reactive microglia and complement proteins, Brain Res. 707(2):196-204, 1996.
• Gemmell, C. A flow cytometric immunoassay to quantify adsorption of complement activation products on artificial surfaces, J Biomed Mater Res 37, 474-480, 1997.
• Solzner, S., Lemerre, C. et al. Temporal accural of complement proteins in Amyloid plaques in patients with Down syndrome with Alzheimer's Disease, Am J Path 156:489-499, 2000.
• Barbosa, A., et al. Immune evasion of lptospira species by acquisition of human complement regulator C4BP. Infection and Immunity 77.3:1137-143 (2009)
• Yasojima, K., et al. Up Regulated Production and Activation of the Complement System in Alzheimer's Disease Brain. Am J Path 154:927-935 (1999).
• Stoltzner, S.E. Temporal Accrual of Complement Proteins in Amyloid Plaques in Down's Syndrome with Alzheimer's Disease.
• Desvaux, D., et al. Acute Renal Allograft Rejection with Major Interstitial Oedema and Plasma Cellrich Infiltrates: High A´-interferon Expression and Poor Clinical Outcome. Nephrol Dial Transplant 19:933-939 (2004).
• Nordstrom, T., et al. The Emerging Pathogen Moraxella Catarrhalis Interacts with Complement Inhibitor C4b Binding Protein through ubiquitous surface proteins A1 and A2. J Immunol 173:4598-4606 (2004).
• Pascher, A., et al., Immunopathological observations after xenogenic liver perfusions using donor pigs transgenic for human decay-accelerating factor 1,2. Transplantation 643.3: 384-91 (1997)

• Bigler, C. et al. Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells. Journal of Immunology 183:512-521 (2009)
• Baldwin, W. et al. "Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes." Transplantation 68(6) 894-900 (1999).
• Rosoklija, G.B. et al. "Local activation of the complement system in endoneurial microvessels of diabetic neuropathy" Acta Neuropath 99:55-62 (2000).
• Yasojima, K. et al. Human heart generates complement proteins that are upregulated and activated after myocardial infarction. Circulation research 83:860-69 (1998).

参考文献：Alternative Pathway

• Wright, A., Morrison, S. Effect of C2 Associated Carbohydrate structure of Ig Effector function: studies with chimeric mouse human IgG1 Antibodies in glycosylation mutants of chinese hamster ovary cells, J. Immunol 160:3393-3402, 1998.
• Hourcade, D., et al. A conserved element in the serine protease domain of complement Factor B, J Bio Chem 273:25996-26000, 1998.
• Gold, B. et al. Variation in Factor B (FB) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nature Genetics 38(4):458-462 (2006).
• Rostagno, A. et. al. Complement activation in chromosome 13 dementias. Similarities with alzheimer's disease. J Biol Chem 277(51):49782-49790 (2002).
• Yasojima, K. et. al. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterio Throm Vas Biol 21(7):1214-1219 (2006).
• Gemmell, CH. A flow cytometric immunoassay to quantify adsorption of complement activation products (iC3b, C3b, SC5b-9) on artificial surfaces. J Biomed Mater Res 37(4):474-480 (1997).
• Ragupathi, G. et. al. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J Immuno 174(9):5706-5712 (2005).

• Hourcade, D., et al. A conserved element in the serine protease domain of complement Factor B, J Bio Chem 273:25996-26000, 1998.

参考文献：Terminal Complement Complex

• Sandoval, A., Rong A., et al. Distal recognition site for classical pathway convertase located in the C345C/Netrin module of complement component C5, J. Immunol 165:2 1066-1073., 2000.
• Barbashov, S. Wang, C., Nicholson-Weller, A. Serum amyloid P component forms a stable complex with human C5b-6, J. Immunol. 158:3830-3835, 1997.
• Barilla-LaBarca, ML. et al. Role of membrane cofactor protein (Cd46) in regulation of C4b and C3b deposited on cells. J Immunol. 168(12):6298-6304 (2002).

• Barbashov S., Wang C., Nicholson-Weller, A. Serum amyloid P component forms a stable complex with human C5b-6, J. Immunol. 158:3830-3835, 1997.
• Thorgersen, EB. et al. Inhibition of complement and CD14 attenuates the Escherichia coli-induced inflammatory response in porcine whole blood. Infect Immun. 77(2):725-732 (2002).
• Plested, JS. and Granoff, DM. Vaccine-induced opsonophagocytic immunity to Neisseria meningitides group B. Clin Vaccine Immunol. 15(5):799-804 (2008).
• Ragupathi, G. et al. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity . J Immunol. 174(9):5706-5712 (2005).

• Stahl, G., Agah, A., et al. Isolation, characterization and cloning of porcine complement component C7, J Immunol 165:8 4178-4184, 2000.
• Barbashov, S., Wang C., Nicholson-Weller, A. Serum amyloid P component forms a stable complex with human C5b-6, J. Immunol. 158:3830-3835, 1997.
• Werhuis, R., Vandervalk, P. Complement activation in amyloid plaques in Alzheimer's Disease does not proceed further than C3, Virchos Arch 426:603-610, 1995.
• Attia AS. et. al. Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the comple- ment cascade. Infect Immun. 73(3):1597- 1611 (2006).

• Barbashov, S., Wang C., Nicholson-Weller, A. Serum amyloid P component forms a stable complex with human C5b-6, J. Immunol. 158:3830-3835, 1997.

• Barbashov, S., Wang C., Nicholson-Weller, A. Serum amyloid P component forms a stable complex with human C5b-6, J. Immunol. 158:3830-3835, 1997.
• Verhuis, R., van der Valk, P. Complement activation in amyloid plaques in Alzheimer's Disease does not proceed further than C3, Virchos Arch 426:603-610, 1995.

• TScambi C, Ugolini S, Jokiranta TS, De Franceschi L, Bortolami O, et al. (2015) The Local Complement Activation on Vascular Bed of Patients with Systemic Sclerosis: A Hypothesis-Generating Study. PLOS ONE 10(2): e0114856.
• Loeffler DA, Camp DM, Bennett DA. Plaque complement activation and cognitive loss in Alzheimer's disease. Journal of Neuroinflammation. 2008;5:9.
• Merri, A., Junnikala, S. Exceptional Resistance of Human H2 Gioblastoma Cells to Complement Mediated Killing by Expression and Utilization of Factor H and Factor H Like Protein 1, J Immunol 164:11 6075-6081, 2000.
• Stoltzner, S., Lemerre, C. et al. Temporal accrual of complement proteins in Amyloid plaques in patients with down's syndrome with Alzheimer's Disease, Am J Path 156:489-499, 2000.
• Wright, A., Morrison, S. Effect of C2 Associated Carbohydrate structure of Ig Effector function: studies with chimeric mouse human IgG1 Antibodies in glycosylation mutants of chinese hamster ovary cells, J. Immunol 160:3393-3402, 1998.
• Gemmell, C. A flow cytometric immunoassay to quantify adsorption of complement activation products on artificial surfaces, J Biomed Mater Res 37, 474-480, 1997.
• Rogers, J., N. Cooper, et al. Complement Activation by ss-amyloid in Alzheimer disease, PNAS 89:10016-10020, 1992.
• Depisch, R. V. Schmitt et al. Fluid phase generation of terminal complement complex as a novel index of bio-incompatibility, Kidney Int'l, 37, 696-627 1990.
• Yasojima, K. et al. Human heart generates complement proteins that are upregulated and activated after myocardial infarction. Circ Res 83(8):860-869 (1998).

参考文献：Regulatory Proteins

• Roos, A. et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 17:1724-1734 (2006).
• Grosskinsky, S. et al. Human complement regulators C4b-Binding Protein and C1 Esterase Inhibitor interact with a novel outer surface protein of Borrelia recurrentis. PLOS Neglected Tropical Diseases 4(6):e698 (2010)

• Kraiczy, P., Würrzner, R. Complement escape of human pathogenic bacteria by acquisition of complement regulators. Mol Immunol 43:21-44 (2006).
• Sivaprasad, S. and Chong, N.V. The complement system and age related macular degeneration. Eye (2006), 1-6.
• Atkinson, J.P., et al. Complement factor H and the hemolytic uremic syndrome. JEM Vol. 204, No. 6, June 11, 20071245－1248.¨z
• Fedarko, N.S., et al. Factor H binding to bonesialoprotein and osteopontin enables tumor cell evasion of complement mediated attack. JBC 27%:22 (2000).
• Hageman, G.S., et al. A common haplotype in complement regulatory gene Factor H predisposes individuals to age related macular degeneration. PNAS 102:7227-7232 (2005).
• Dave, S., et al. Dual roles of PSPC a surface protein of streptococcus pneumoniae in binding human secretory IgA and Factor H. J Immunol 173:471-477 (2004).
• Fakhouri, F., et al. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney International 78.3 (2010): 279-86

• Pangburn M.K. Differences between the binding sites of the complement regulatory proteins DAF, CR1 and Factor H on C3 Convertases, J Immunol 136:6, 1986.
• Kraiczy P, Würrzner, R. Complement escape of human pathogenic bacteria by acquisition of complement regulators, Mol Immunol 43:31-44, 2006.
• Atkinson, J.P., et al. Complement factor H and the hemolytic uremic syndrome, JEM 204:6, 1245-1248, 2007.
• Sivaprasad, S. and Chong, N.V. The Complement system and age-related macular degeneration, Eye 1-6, 2006.
• Jokiranta, T.S., et al. Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti factor H antibodies: evidence for multiple interactions between H and surface bound C3b, FEBS Ltr 393(2-3):297-302, 1996.
• Junnikkala S., et al. Exceptional resistance of Human H2 Glioblastoma Cells to Complement Mediated Killing by Expression and Utilization of Factor H and Factor H Like Protein I, J Immunol 164, 2000.
• Cheng Z., et al. Complement Factor H as a Marker for Detection of Bladder Cancer, Clin Chem 51:5, 2005.

• Pangburn, M.K. Differences between the binding sites of the complement regulatory proteins DAF, CR1 and Factor H on C3 Convertases, J Immunol 136:6, 1986.
• Kraiczy P, Würrzner, R. Complement escape of human pathogenic bacteria by acquisition of complement regulators, Mol Immunol 43:31-44, 2006.
• Atkinson, J.P., et al. Complement factor H and the hemolytic uremic syndrome, JEM 204:6, 1245-1248, 2007.
• Sivaprasad, S. and Chong, N.V. The Complement system and age related macular degeneration, Eye 1-6, 2006.
• Jokiranta, T.S., et al. Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti-factor H antibodies: evidence for multiple interactions between H and surface bound C3b, FEBS Ltr 393(2-3):297-302, 1996.
• Junnikkala, S. et al. Exceptional resistance of Human H2 Glioblastoma Cells to Complement Mediated Killing by Expression and Utilization of Factor H and Factor H Like Protein I, J Immunol 164, 2000.
• Cheng Z., et al. Complement Factor H as a Marker for Detection of Bladder Cancer, Clin Chem 51:5, 2005.

• Shiraishi, M. et al. Improved hepatic microcirculation by human soluble urinary thrombomodulin in the xeno-perfused porcine liver. Transplantation 731:1046-1050 (2001).
• Harboe, M. et al. The role of properdin in zymosan- and Escherichia coli-induced complement activation. J Immunol 189(5):2606-2613 (2012).

• Shiraishi, M. et al. Improved hepatic microcirculation by human soluble urinary thrombomodulin in the xeno-perfused porcine liver. Transplantation 731:1046-1050 (2001).

• Rosoklija, GB. et al. Local activation of the complement system in endoneurial microvessels of diabetic neuropathy. Acta Neuropathol 99(1):55-62 (2000).
• Verhuis, R. et al. Complement activation in amyloid plaques in Alzheimer's Disease does not proceed further than C3. Virchows Arch 426(6):603-610 (1995).